

Roswell Park Oncology Year-in-Review 2026: What Changed, What's Next

Disclosure to Learners updated on 6/25/26

Financial Relationships of Planners & Presenters: The following planners and presenters have either indicated financial relationships with ineligible companies (any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) or that no financial relationships exist. Policies and guidelines for identifying and mitigating relevant financial relationships of planners and presenters involved in accredited continuing education are **in compliance** with the ACCME *Standards for Integrity and Independence in Accredited Continuing Education*.

The following planners or presenters have disclosed financial relationships:	
Role and Name	Financial Relationships
Activity Director: Igor Puzanov, MD, MSCI	<u>Consultant:</u> IO Biotech <u>Publicly traded stockholder:</u> IDEAYA Biosciences
Activity Director: Prantesh Jain, MD	<u>Consultant:</u> Johnson & Johnson; Molecular Partners; AstraZeneca <u>Speaker:</u> SignaMD
Presenter: Emese Zsiros, MD, PhD	<u>Advisory Board member:</u> Merck; AbbVie; Eisai; Corcept Therapeutics; 92Biotech <u>Consultant:</u> Iovance Biotherapeutics; NextCure; Takeda Pharmaceuticals; Outpace Bio; Apellis Pharmaceuticals <u>Researcher:</u> Merck <u>Clinical trial support:</u> Celldex Therapeutics
Presenter: Aarti Bhatia, MD, MPH	<u>Advisor:</u> Adcendo; Regeneron; Merus <u>Researcher:</u> Boehringer Ingelheim; Genentech
Presenter: Saby George, MD	<u>Consultant:</u> Exelixis; Astellas; Bristol Myers Squibb; Eisai; Bayer Healthcare Pharmaceuticals; Janssen Global Services; Merck; Sanofi; AstraZeneca; Novartis; GlaxoSmithKline <u>Researcher:</u> Merck; Novartis; Gilead Sciences; Aveo Pharmaceuticals; Seagen; Bayer Healthcare Pharmaceuticals; BioTek; Gilead Sciences; Bristol Myers Squibb; Eisai; Exelixis
Presenter: Alok Khorana, MD	<u>Consultant:</u> Regeneron; Novartis; Sirius; Alnylam; Bristol Myers Squibb; Pfizer; Sanofi
Presenter: Francisco Hernandez-Ilizaliturri, MD	<u>Advisory Board member:</u> Bristol Myers Squibb; Celgene; AbbVie; ADC Therapeutics; Amgen; Dava Oncology; Epizyme; Pharmacyclics; Gilead Sciences; Incyte; MorphoSys; Kite Pharma; Novartis <u>Researcher:</u> Incyte; Celgene; AbbVie; Eli Lilly
Presenter: Sheheryar Kabraji, BM Bch	<u>Consultant:</u> Daiichi Sankyo; AstraZeneca; Gilead Sciences
Presenter: Benjamin Switzer, DO, MS	<u>Consultant:</u> Bristol Myers Squibb
All of the relevant financial relationship(s) listed have been mitigated.	

The following planners and presenters do not have any relevant financial relationships with ineligible companies:	
CME Role	Names
Activity Coordinator:	Jennifer Allen
Planners:	Kelley Shannahan; Ashley Snowden; Jackson Taylor
Presenter:	Ajay Gupta, MD
Reviewer & Moderator:	Stephanie Tzetzto, PhD

As of 6/25/26, commercial support has not been received for this activity.